Aardvark Therapeutics Q1 net loss widens

Aardvark Therapeutics

07/05/2026 13:14

Overview

US biopharma reported Q1 net loss widened

Q1 operating expenses rose, driven by higher ARD-101 development and personnel costs

Outlook

Company's cash position projected to fund operations into mid-2027

Result Drivers

HIGHER R&D SPENDING - Q1 R&D expenses rose mainly due to increased external costs for ARD-101 development and higher personnel costs

INCREASED ADMINISTRATIVE COSTS - G&A expenses rose due to higher personnel, legal, and public company costs

Company press release: ID:nGNX9wFqcY

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
Miss
-$21.59 mln
-$18.27 mln (9 Analysts)
Q1 Income from Operations
-$22.46 mln
Q1 Operating Expenses
$22.46 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)